Analyst Reco. Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
12.78 ^USD	+0.39%		+3.40%	+23.84%

12/04	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT
12/04	Sector Update: Health Care	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nurix Therapeutics Prices Upsized Stock Offering at $15 a Share	12/04	MT
Baird Adjusts Price Target on Nurix Therapeutics to $25 From $24, Maintains Outperform Rating	11/04	MT
RBC Lifts Price Target on Nurix Therapeutics to $23 From $22, Keeps Outperform Rating, Speculative Risk Qualifier	11/04	MT
Morgan Stanley Adjusts Nurix Therapeutics' Price Target to $10 From $9, Keeps Equalweight Rating	26/02	MT
HC Wainwright Cuts Nurix Therapeutics Price Target to $19 From $35, Maintains Buy Rating	20/02	MT
RBC Cuts Price Target on Nurix Therapeutics to $22 From $24, Keeps Outperform, Speculative Risk	16/02	MT
RBC Cuts Price Target on Nurix Therapeutics to $24 From $29, Keeps Outperform, Speculative Risk	02/11	MT
RBC Trims Price Target on Nurix Therapeutics to $29 From $30, Keeps Outperform, Speculative Risk	13/23/13	MT
HC Wainwright Adjusts Price Target on Nurix Therapeutics to $35 From $33, Keeps Buy Rating	08/23/08	MT
HC Wainwright Adjusts Nurix Therapeutics Price Target to $33 From $53, Maintains Buy Rating	24/23/24	MT
Morgan Stanley Adjusts Price Target on Nurix Therapeutics to $12 From $11, Maintains Equal-Weight Rating	17/23/17	MT
Barclays Initiates Nurix Therapeutics at Overweight With $20 Price Target	09/23/09	MT
Oppenheimer Initiates Coverage on Nurix Therapeutics With Outperform Rating, $25 Price Target	28/23/28	MT
Stifel Adjusts Price Target on Nurix Therapeutics to $31 From $37, Maintains Buy Rating	14/23/14	MT
JPMorgan Chase Adjusts Price Target on Nurix Therapeutics to $36 From $37, Maintains Overweight Rating	13/23/13	MT
Berenberg Bank Adjusts Nurix Therapeutics' Price Target to $30 From $48, Maintains Buy Rating	13/23/13	MT
Needham Trims Price Target on Nurix Therapeutics to $31 From $32, Maintains Buy Rating	10/23/10	MT
RBC Cuts Price Target on Nurix Therapeutics to $30 From $39, Maintains Outperform, Speculative Risk	10/23/10	MT
Morgan Stanley Starts Nurix Therapeutics at Equalweight with $11 Price Target	11/22/11	MT
HC Wainwright Trims Nurix Therapeutics' Price Target to $53 From $54, Maintains Buy Rating	07/22/07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Analyst Reco.

Filters